Published on 13 Nov 2023 on GuruFocus.com via Yahoo Finance
Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments
Net loss of $17.7 million for Q3 2023, with a net loss per share of $0.63.Research and development expenses increased to $13.3 million for Q3 2023.Cash, cash equivalents, and short-term investments totaled $188.8 million as of September 30, 2023.Company expects cash runway to extend into 2026, inclusive of recent underwritten offering proceeds.
On November 13, 2023, Astria Therapeutics Inc (NASDAQ:ATXS) released its 8-K filing, announcing its financial results for the third quarter ended September 30, 2023, and providing updates on its corporate activities. The company, which focuses on developing therapies for rare and niche allergic and immunological diseases, shared insights into its financial position and the progress of its clinical programs.